

1 **Title Page**

2 **Title:** A novel use of HIV surveillance and court data to understand and improve
3 care among a population of people with HIV experiencing criminal charges in North
4 Carolina 2017-2020

5 **Authors and affiliations:** Elizabeth C. Arant^{1*}, Andrew L. Kavee², Brad Wheeler³,
6 Bonnie E. Shook-Sa⁴, Erika Samoff³, David L. Rosen¹

7 ¹Division of Infectious Diseases, Department of Medicine, School of Medicine,
8 University of North Carolina at Chapel Hill, NC.

9 ² Sheps Center for Health Services Research at University of North Carolina at
10 Chapel Hill, NC.

11 ³North Carolina Department of Health and Human Services, Raleigh, NC.

12 ⁴Department of Biostatistics, Gillings School of Global Public Health, University of
13 North Carolina at Chapel Hill, Chapel Hill, NC.

14 ***Corresponding author**

15 Elizabeth C. Arant (ECA)
16 Elizabeth.arant@unchealth.unc.edu

17
18 **Prior meetings:** This work has been presented in poster form at IDWeek 2023 in
19 Washington, DC

20 **Financial support:** This work was funded by the National Institute of Allergy and
21 Infectious Diseases at the National Institutes of Health ([NIH] Grant Number
22 T32AI007001 to E.C.A and R01A129731 to D.L.R). This research was supported by
23 the University of North Carolina at Chapel Hill Center For AIDS Research (CFAR),
24 an NIH funded program P30AI050410.

25 **Conflicts of interest:** The authors have no conflicts to declare

26 **Running Head:** Criminal charges in people living with HIV

27

28

29

30

31

32

33

34

35

36 **Abstract**

37 Objectives: Objectives: To enumerate the population of people with HIV (PWH) with
38 criminal charges and to estimate associations between charges and HIV outcomes

39 Methods: We linked statewide North Carolina criminal court records to confidential
40 HIV records (both 2017-2020) to identify a population of defendants with diagnosed
41 HIV. We used generalized estimating equations to examine changes in viral
42 suppression (outcome) pre-post criminal charges (exposure), adjusting for other
43 demographic and legal system factors.

44 Results: 9,534 PWH experienced criminal charges. Compared to others with
45 charges, PWH were more likely to be male and report Black race. The median
46 duration of unresolved charges was longer for PWH. When adjusting for
47 demographic factors, the period following resolution of charges was modestly
48 associated with an increased risk of viral suppression (aRR 1.03 (95% confidence
49 interval 1.02-1.04) compared to the pre-charge period.

50 Conclusions: A significant portion of PWH in NC had criminal charges during a
51 three-year period, and these charges went unresolved for a longer time than those
52 without HIV. These preliminary findings raise questions regarding whether PWH
53 have appropriate access to legal services.

54

55 **Key words:** HIV/AIDS, criminal justice, legal, epidemiology

56

57

58

59

60

61

62

63

64

65 **Introduction**

66 Criminal system involvement in the United States (US) is common, with about 2.2
67 million people incarcerated in state and federal prisons and jails in a given day in
68 2019¹. Formerly incarcerated people often have difficulty accessing and utilizing
69 healthcare, resulting in negative impacts on physical and mental health^{2,3}. For
70 people with HIV (PWH) specifically, the period following prison or jail incarceration
71 has been associated with loss of viral suppression and decreased engagement in
72 HIV care^{4,5}.

73 Although millions of people are incarcerated in the US annually, this population
74 represents a fraction of all Americans who have some type of criminal record⁶.
75 Compared to incarcerations, less is known about the effect of lower-level legal
76 involvement. Others have hypothesized about the burden that arrests, charges,
77 conviction, and sentencing have on physical and emotional health⁷⁻⁹. However, little
78 is known about the impact of criminal charges in the absence of incarceration on HIV
79 outcomes.

80 The goal of the current study was to enumerate the population of PWH who face
81 charges within the criminal legal system and to estimate the association between
82 this involvement and HIV outcomes. To do so, we used a de-identified linked
83 database primarily composed of longitudinal North Carolina (NC) court records and
84 confidential state HIV diagnoses and viral load records. Our central hypothesis is
85 that being charged in the court system will be associated with declines in viral
86 suppression, as court involvement could have a direct negative impact on disease
87 management and serve as an indicator for behaviors that can impede disease

88 management. This analysis represents an important step in understanding the
89 relationship between legal system involvement and health for PWH.

90 **Methods**

91 *Data source and charge definition*

92 We utilized data from linked NC court, jail, and HIV surveillance records. This data
93 linkage process has been described previously¹⁰. In summary, to identify a cohort of
94 adult (aged ≥ 18) PWH in NC charged in criminal court between January 2017-
95 February 2020, we linked the following datasets: statewide court records, jail
96 incarceration records from 26 of 100 counties, and statewide confidential department
97 of public health (DPH) records of all NC PWH. We obtained court records from the
98 NC Administration Office of the Court. We derived jail incarceration histories using a
99 technique called web-scraping, in which automated ‘bots’ collect incarceration data
100 from public jail rosters. We then linked jail and court records using identifiers and
101 provided these records to the NC DPH. NC DPH personnel linked these records to
102 the state’s confidential HIV records, (using first and last name, DOB, and when
103 available, last 4-digits of social security number), which included statewide viral load
104 (VL) laboratory results and dates. NC DPH then provided us with linked and
105 deidentified court and incarceration records, from which we estimated the number of
106 adult PWH with criminal court records in all 100 NC counties. We used this de-
107 identified database of defendants, both with and without HIV, as the data source in
108 our analysis. The court records assign a unique identifier based on the defendant’s
109 name and the county where a charge is initiated, therefore it is possible that one
110 unique participant could be assigned multiple court identifiers if he/she has cases in

111 multiple counties or is identified under a different name. For defendants with HIV, we
112 addressed this by removing cases where a single DPH record was linked to multiple
113 court records (n=34). For defendants without HIV, we did not have a linked DPH
114 record and were therefore unable to eliminate redundant identifiers. Since this was a
115 rare occurrence among PWH (i.e., < 0.5% of court records), we assumed that this
116 was similarly rare among those without HIV and therefore unlikely to affect our
117 findings.

118 In the NC court system, a defendant may face one or more criminal charges arising
119 from a single incident. Individual charges can be adjudicated at the same time or
120 sequentially. People may also incur new charges before existing charges are
121 adjudicated. For the purpose of the current analysis, we considered a charge period
122 to be a continuous period in which a person had at least one unresolved charge.

123 *Covariates*

124 Both court and HIV record demographic information included DOB, race and
125 ethnicity, and sex. HIV records included self-reported HIV transmission group and
126 HIV VL results and dates. Of note, race and ethnicity data were reported slightly
127 differently in the court and DPH records. Most notably, the court records included
128 Hispanic as a race category (alongside White, Black, Other, and Unknown), whereas
129 DPH included separate variables for race and ethnicity. Among PWH, we quantified
130 the discordance between these two classification schemas (Supplementary Table 1).
131 For consistency in our main analysis we reported race-ethnicity characteristics using
132 data from the court records only.

133 *Outcomes*

134 For the primary outcome of VL suppression, we adopted the NC DPH's definition of
135 VL suppression (<200 copies HIV RNA/ml) and un-suppression (\geq 200 copies HIV
136 RNA/mL or no record of a VL test within 12 months).

137 *Statistical Analysis*

138 The goal of our study was to identify the population of adult diagnosed PWH in NC
139 charged in criminal court 2017-2020 and to estimate the association between this
140 involvement and HIV viral suppression. We used descriptive statistics to report
141 baseline characteristics, number of discrete periods of non-overlapping charges, and
142 duration of unresolved charge period (days). We compared these characteristics by
143 known HIV status at the time of the first charge during the study period. For PWH
144 who experienced a single discrete period of criminal charges during the period
145 studied (94.1%), we calculated the proportion with viral suppression in the 12
146 months before initiation of and after resolution (pre-post) of criminal charges, using
147 the VLs closest to the charge period. We included only PWH who were diagnosed at
148 least 12 months prior to charges and had at least 12 months of follow-up following
149 the disposition of charges. We coded PWH without a documented VL as
150 unsuppressed. We implemented a log-binomial model using generalized estimating
151 equations (GEE) to compare the proportion of viral suppression pre-post charges,
152 adjusting for demographic (age, race, sex) and HIV-specific (transmission category)
153 factors. We reported crude risk ratios (RRs), adjusted risk ratios (aRRs), and 95%
154 confidence intervals (CI's). We stratified the analysis of the entire population by the

155 number of days that charges remained unresolved to determine whether our results
156 differed by duration of unresolved charges.

157 Although our primary aim was to understand the relationship between having
158 criminal charges and viral suppression in PWH in NC, we recognized that some with
159 charges would have spent time incarcerated. Therefore, among people charged in
160 the 26 counties for which we had jail incarceration data, we conducted a sensitivity
161 analysis examining the association between charges and viral load suppression,
162 comparing stratified estimates of the RR and aRR between those with and without
163 an incarceration record.

164

165 *Ethics approval/Consent*

166 This study was approved by the University of North Carolina at Chapel Hill
167 institutional review board #17-0946. The IRB waived the requirements for informed
168 consent. Data were fully anonymized before being accessed by the study team, and
169 authors did not have access to information that could identify individual participants
170 either during or after data collection. Data were accessed for research purposes
171 between 5/1/2/21 and 7/1/2023.

172 Results

173 *Full analysis*

174 A total of 2,436,732 unique defendants experienced criminal charges in NC 2017-
175 2020; 9,534 (0.4%) of these were PWH . Compared to those without HIV

176 (n=2,427,198), PWH were more likely to self-identify as male (78.8% vs 69.4%). A
177 larger number of PWH with criminal charges were Black compared to those without
178 HIV (77.1% vs 36.8%). PWH had a median age of 41 years (interquartile range
179 [IQR] 29-51) compared to 36 years (IQR 27-47) for those without HIV. A majority of
180 PWH and those without HIV had a single period of criminal charges during the study
181 period (94.1% vs 92.7%). PWH had a longer period of days with unresolved charges
182 compared to those without HIV (median of 68 days vs 37 days). The most common
183 mode of HIV acquisition reported at the time of diagnosis were men who have sex
184 with men (MSM) (45.2%); 28.4% had no transmission information recorded (Table
185 1).

186 Of the 9,534 PWH with criminal charges, 3,072 (32%) were excluded from
187 multivariable analysis, because they did not contribute 12 months of observable
188 person-time before and after the period of criminal charges. An additional 35 (0.4%)
189 were excluded due to missing a value for at least one covariate, leaving 6,427 (67%)
190 available for analysis. PWH who had full follow-up periods were similar to those
191 without based on distribution of demographic and HIV-specific characteristics in
192 each demographic category (Supplementary Table 2). Among those with complete
193 follow-up periods, 662 (10.2%) had a missing viral load in both the pre- or post-
194 charge period and were therefore coded as unsuppressed.

195 In an unadjusted comparison, a slightly larger proportion of PWH experienced viral
196 suppression in the post-charge period compared to the pre-charge period (72% vs
197 70%, $p<0.05$), corresponding to a RR of 1.03 (95% CI 1.02-1.05). When adjusting for
198 demographic and HIV-specific factors, the period following resolution of charges was

199 similarly associated with an increased risk of viral suppression, aRR 1.03 (95% CI,
200 1.02-1.04). Factors negatively associated with viral suppression in the multivariable
201 model included Black race (aRR 0.92 [95% CI 0.90-0.95]) compared to White race
202 and self-reported HIV acquisition via heterosexual contact (aRR 0.92 [95% CI 0.88-
203 0.97]) or IDU (aRR 0.85 [95% CI 0.80-0.90]) compared to MSM. Factors positively
204 associated with viral suppression included those aged 60-69 (aRR 1.27 [95% CI
205 1.19-1.34]) compared to those aged 18-29 (Table 2). When stratifying the analysis
206 by duration of unresolved charges, those with the longest period of unresolved
207 charges (300+ days, n=604 [10%]) were more likely to achieve viral suppression
208 (RR 1.06 [95% CI, 1.01-1.12) compared to those with the shortest period of
209 unresolved charges (0-99 days, n=4,237 [66%]), RR 1.03 [95% CI, 1.01-1.04],
210 although the proportion with viral suppression was overall lower in both the pre- and
211 post-charge periods among those with charges 300+ days (64.4% and 68.1%,
212 respectively), Supplementary Table 3.

213 *Sensitivity analyses*

214 To better understand whether jail incarceration affected the relationship between
215 charge period and viral suppression, the above analyses were conducted in a subset
216 of PWH with charges in the 26 NC counties where jail incarceration data were
217 available. These results were stratified by jail incarceration status.

218 Among these counties, 157,049 people experienced criminal charges during 2017-
219 2020, of which 1,304 (0.8%) were PWH. There were some demographic differences
220 among this limited population of PWH and the overall population of PWH with
221 criminal charges (Supplementary Table 4). We found that when stratifying PWH by

222 jail incarceration status, the relationship between charge period and viral load was
223 similar in both groups. This was true both for unadjusted analyses (RR: 0.98 [95% CI
224 0.89-1.08] among jail incarcerated, RR: 0.97 [95% CI 0.97 (0.99-1.09)] among those
225 without jail incarceration) and adjusted analyses (Supplementary Table 5). We note
226 that for all estimates, the association was not statistically significant and differed in
227 direction from the estimated associations in our main analysis.

228 **Discussion**

229 A large proportion of people in the US have some type of criminal record, and history
230 of even a minor criminal record can have negative impacts on physical and mental
231 health^{6,8,9,11}. Most people facing criminal charges are not incarcerated or are
232 incarcerated for brief periods. Through an innovative linkage of HIV surveillance and
233 court data, we identified a population of diagnosed PWH with any criminal charges
234 and examined the relationship between having criminal charges—including those
235 with no or short incarcerations—with HIV outcomes. We found that over a three-
236 year period nearly 10,000 PWH in NC experienced criminal charges, which in the
237 year 2019, corresponded with about 1 in 5 PWH. The resolution of charges typically
238 required 80% more time among PWH than among those without HIV. Contrary to
239 our expectation, the period immediately following the resolution of charges was
240 associated with a modest increase in the proportion with viral suppression.

241 This study represents one of the largest ever of legal involvement among PWH.
242 While one study evaluated linkage to care in almost 10,000 PWH following release
243 from US jails¹², other studies of incarcerated or formerly incarcerated PWH have

244 been smaller^{4,5,13}. No other study has evaluated associations between criminal
245 charges without incarceration and HIV outcomes.

246 Existing studies of HIV among justice-involved populations have shown that the
247 prevalence of HIV in jails and prisons is about three to five times that of the general
248 US population (with most HIV acquisitions occurring pre-incarceration)^{14,15}.

249 Compared to studies of incarcerated populations, we found that the prevalence of
250 HIV among those with criminal charges (0.4%) was similar to the prevalence of HIV
251 in the general population¹⁶. Nevertheless, a relatively large number of PWH
252 experienced charges. PWH experience a disproportional amount of social and
253 economic inequality¹⁷⁻¹⁹, and our finding that charges among PWH took longer to
254 resolve compared to those without HIV could be explained by PWH's more modest
255 resources. Other possibilities are that PWH had more serious charges that required
256 longer to resolve, or that they were disproportionately charged in court districts that
257 were slower to process cases. Regardless of the ultimate explanation, our findings
258 suggest that PWH may, as a population, benefit from healthcare practice models
259 that include a medical-legal partnership (MLP)²⁰.

260 MLPs are healthcare delivery innovations that embed civil legal aid expertise into the
261 health care team and focus on prevention by addressing upstream social and legal
262 problems that affect health²¹. Such partnerships could be expanded to include
263 criminal legal aid, particularly in locations and patient populations with frequent or
264 prolonged legal contact. A group in Rhode Island has expanded the MLP model to
265 include criminal cases, and they have reported positive experiences²². While special
266 considerations would need to be made for PWH given the sensitivity and stigma that

267 an HIV diagnosis carries in society, this novel criminal MLP model serves as an
268 example of a potential multidisciplinary support mechanism for PWH experiencing
269 criminal charges, and such services could potentially be integrated into existing HIV
270 services.

271 Racial disparities pervade the criminal justice system; Black Americans are
272 disproportionately arrested and convicted and are given harsher sentences
273 compared to Whites who commit the same crimes^{23,24}. There are also significant
274 racial disparities in the HIV epidemic^{18,25}. Systemic racism, HIV stigma, and
275 economic and systemic barriers to health care that underlay disparities related to
276 HIV care likely compound the existing racial disparities within the criminal justice
277 system. In our study, we found a higher proportion of Black PWH with criminal
278 charges compared to the general population of PWH in NC¹⁶. While not unexpected,
279 our finding of a disproportionate number of Black defendants with HIV suggests that
280 this compounding of racial disparities affects even early legal-system involvement for
281 PWH. Combatting and addressing systemic racism both in the HIV epidemic
282 and in the criminal justice system are crucial to addressing disparities in these
283 spaces, and HIV clinics could benefit from the support that an MLP model may
284 provide to address upstream barriers related to systemic racism.

285 Our finding of a mild improvement in the proportion of viral suppression following the
286 period of criminal charges was unexpected. While small (RR=1.03), this trend was
287 present in both crude and adjusted analyses. Prior literature pertaining to HIV
288 outcomes of PWH with legal involvement primarily focuses the effect of prison or jail
289 incarcerations on HIV outcomes. Most studies show that virologic suppression

290 improves during the prison incarceration period, likely due to access to HIV care and
291 mental health services and a structured daily routine²⁶. While HIV care and ART are
292 less consistently available during jail incarcerations, jail lengths of stay are typically
293 shorter (median of 3 days²⁷), therefore the peri-incarceration period itself likely plays
294 less of a role in viral suppression. Jail incarceration data were only available to us for
295 a subset of counties. In these counties, a higher proportion of PWH with criminal
296 charges were incarcerated compared to those without HIV (75.8% vs 67.8%). In our
297 sensitivity analysis, the association between charge period and viral suppression
298 was similar among those with and without record of a jail incarceration; this
299 consistency suggests that incarceration did not modify the overall association
300 between charge period and viral suppression. The direction of the charge period-
301 viral suppression association in our sensitivity analysis was in the opposite direction
302 of the association in our main analysis, suggesting that this association may vary by
303 county.

304 While relatively minor offenses usually do not incur other post-sentencing sanctions,
305 these low-level forms of justice system contact can negatively impact physical and
306 mental health throughout the continuum of contact, particularly for those already
307 experiencing social and health disparities^{8,11}. We anticipated that the period
308 following criminal charges would be associated with a decline in the proportion of
309 PWH with viral suppression; instead, we found a small increase in the proportion of
310 those with viral suppression following the period of criminal charges. It is likely that
311 most of the criminal charges in our study were minor offenses or misdemeanors,
312 such as traffic violations, that may have had little impact on HIV outcomes. When

313 stratifying the analysis by duration of unresolved charges, however, those with the
314 longest period of charges (300+ days) were more likely to achieve viral suppression
315 compared to those with shorter charge periods. More investigation is needed to
316 understand the relationship between type and duration of charges as they relate to
317 HIV outcomes.

318 The proportion of PWH with viral suppression in our population was in between that
319 of all PWH in NC in 2020 (66%) and those considered in care (85%)²⁸. Given that a
320 relatively small proportion (10%) of our population had missing viral load data, it may
321 be more meaningful to compare the rate of viral suppression to the “in-care”
322 population of PWH in NC. The justice-involved PWH in our study had a lower
323 proportion of viral suppression compared to in-care PWH in NC, which is more
324 consistent with our hypotheses regarding the effect of lower-level legal involvement
325 on HIV outcomes. An alternative etiology relates to limitations of HIV surveillance
326 data. It is possible that individuals who are still in care in another state or who have
327 died may continue to contribute to the surveillance denominator, leading to an
328 underestimation of the true rate of viral suppression. The NC DPH mitigates this
329 issue using active surveillance among those originally identified as out-of-care. For
330 example, in 2020, 26% of people originally deemed out-of-care were identified by
331 NC DPH as living in another state or as having died²⁸. Nevertheless, unidentified out-
332 migrations and deaths may still impact our comparisons of viral suppression among
333 PWH with and without court involvement.

334 One limitation of our study is its reliance on surveillance data. Limitations of this
335 approach have been discussed previously²⁹⁻³¹. In our full analysis, about 10% of the

336 population had missing VL data in both the pre- and post- charge periods. Prior
337 literature suggests that, there is underreporting of VL to state surveillance systems³².
338 As a result, viral suppression is underestimated. While there was considerable
339 variation with laboratory reporting compliance in NC when the surveillance database
340 was first created³³, we believe that modern laboratory platforms and automated
341 reporting have minimized missing data during the study period. Clinicians may
342 decide to reduce VL testing frequency due to more effective and less toxic ART
343 regimens, patient convenience, or cost³⁴. Nevertheless, with our use of a full 12-
344 months for our pre- and post-charge time frame, we believe that these factors
345 resulted in “missing” VLs infrequently.

346 As discussed above, some PWH may receive VL monitoring in different states due
347 to convenience or migration, and excluding or assuming a “worst case” HIV-related
348 outcome for these individuals may result in an overestimation of those who are
349 either out of care or not virally suppressed³⁵. Assuming that those without VL data
350 were not virally suppressed may underestimate the proportion of PWH with viral
351 suppression. When excluding those with a missing VL from the analysis, our
352 estimates were similar to estimates obtained when applying the missing data
353 assumption, suggesting that coding those with missing VL data as unsuppressed
354 had little impact on our results.

355 **Conclusions and Public Health Implications**

356 Legal involvement, from minor offenses to arrests and charges leading to
357 incarceration, is pervasive in the US. While more is known about the negative impact

358 of incarceration on HIV-related outcomes for PWH, a better understanding of the
359 impact of lower-level legal-involvement in this population is needed. In our study, a
360 significant portion of PWH in NC had criminal charges during a three-year period,
361 and these charges went unresolved for a longer time than those without HIV. These
362 preliminary findings raise questions regarding whether PWH have appropriate
363 access to legal services. Greater access to legal care could be facilitated by
364 developing medical-legal partnerships at HIV care sites. Qualitative investigation of
365 the experiences that PWH with criminal charges have with legal representation and
366 their healthcare teams would strengthen our understanding about interventions that
367 may be most beneficial to improving HIV care for this population. To better
368 understand the relationship between the period of criminal charges and HIV care, an
369 important next step would be to incorporate more granular details about the charge
370 itself (type, severity) and the legal outcome of the charge in our analysis. Our
371 investigation, while a preliminary step, reveals insightful information about an
372 understudied population of PWH. Given that a significant number of PWH across the
373 US likely experience criminal charges, ongoing work in this space is crucial for
374 informing care for this population.

375

376

377

Table 1. Baseline characteristics of people with and without HIV who were charged in NC criminal court, 2017-2020.

Group	Non-HIV (n=2,427,198)	HIV (n=9,534)
	n (col%) or median (1 st -3 rd quartiles)	
Sex		
Male	1,685,236 (69.4)	7,516 (78.8)
Female	741,962 (30.6)	2,018 (21.2)
Race		
White	1,067,557 (43.9)	1,860 (19.5)
Black	894,930 (36.8)	7,353 (77.1)
Hispanic	330,205 (13.6)	133 (1.4)
Other or Unknown	136,594 (5.6)	168 (1.8)
Age (years)	36 (27-47)	41 (29-51)
Total number of cases		
1	2,252,747 (92.7)	8,969 (94.1)
2	157,972 (6.5)	549 (5.8)
3 or greater	19,567 (0.8)	16 (0.2)
Charge days	37 (1-129)	68 (1-209)
HIV transmission group		
MSM		4,306 (45.2)
Unknown		2,712 (28.4)
Heterosexual contact		1,367 (14.3)
IDU		722 (7.6)
MSM & IDU		358 (3.8)
Other		69 (0.7)
Abbreviations: NC, North Carolina; MSM, men who have sex with men; IDU, injection drug use; IQR interquartile range		

Table 2. Association¹ between criminal charge period, demographics, and HIV viral suppression, NC 2017-2020 (n=6,427)². Analysis including data from all NC counties.

Characteristic	Adjusted RR (95% CI) ³
Time period	
12 months pre charge	
12 months post charge	1.03 (1.02-1.04)
Age (years)	
18-29	Reference
30-39	1.03 (0.98-1.08)
40-49	1.17 (1.11-1.22)
50-59	1.24 (1.19-1.3)
60-69	1.27 (1.19-1.34)
70 and older	1.19 (0.99-1.43)
Race/Ethnicity	
White	
Black	0.92 (0.90-0.95)
Hispanic	1.05 (0.96-1.16)
Other	0.95 (0.85-1.06)
Sex	
Male	
Female	1.02 (0.98-1.06)
HIV Transmission Category	
MSM	
Heterosexual	0.92 (0.88-0.97)
IDU	0.85 (0.80-0.90)
MSM and IDU	0.88 (0.82-0.95)
Other	0.87 (0.69-0.91)

¹ Multivariable log-binomial estimates. ² Only individuals who contributed person-time to both pre- and post-charge periods and who had a single period of criminal charges were included in model. ³ Adjusted RRs are adjusted for all the variables in the table. Abbreviations: PWH, People Living with HIV; NC, North Carolina; RR, risk ratio; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; IDU, injection drug use. Definitions: Viral Suppression: <200 copies of HIV RNA per milliliter of blood

References

1. Carson E. Prisoners in 2019. U.S. Department of Justice. <https://bjs.ojp.gov/content/pub/pdf/p19.pdf>
2. Wildeman C, Wang EA. Mass incarceration, public health, and widening inequality in the USA. *Lancet*. Apr 8 2017;389(10077):1464-1474. doi:10.1016/s0140-6736(17)30259-3
3. Massoglia M, Pridemore WA. Incarceration and health. *Annual review of sociology*. 2015;41:291.
4. Dumont DM, Brockmann B, Dickman S, Alexander N, Rich JD. Public health and the epidemic of incarceration. *Annual review of public health*. 2012;33:325.
5. Loeliger KB, Meyer JP, Desai MM, Ciarleglio MM, Gallagher C, Altice FL. Retention in HIV care during the 3 years following release from incarceration: A cohort study. *PLoS Med*. Oct 2018;15(10):e1002667. doi:10.1371/journal.pmed.1002667
6. Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. *Am J Public Health*. Jul 2015;105(7):e5-16. doi:10.2105/ajph.2015.302635
7. The Sentencing Project. Americans with Criminal Records. Accessed February 14, 2023. <https://www.sentencingproject.org/app/uploads/2022/08/Americans-with-Criminal-Records-Poverty-and-Opportunity-Profile.pdf>
8. Kohler-Hausmann I. Misdemeanor Justice: Control without Conviction. *American Journal of Sociology*. 2013;119(2):351-393. doi:10.1086/674743
9. Fernandes AD. How far up the river? Criminal justice contact and health outcomes. *Social Currents*. 2020;7(1):29-45.
10. Sugie NF, Turney K. Beyond Incarceration: Criminal Justice Contact and Mental Health. *American Sociological Review*. 2017;82(4):719-743. doi:10.1177/0003122417713188
11. Shook-Sa BE, Hudgens MG, Kavee AL, Rosen DL. Estimating the number of persons with HIV in jails via web scraping and record linkage. *Journal of the Royal Statistical Society: Series A (Statistics in Society)*. 2022;185(S2):S270-S287. doi:<https://doi.org/10.1111/rssa.12909>

12. Sheely A, Kneipp SM. The Effects of Collateral Consequences of Criminal Involvement on Employment, Use of Temporary Assistance for Needy Families, and Health. *Women Health*. 2015;55(5):548-65. doi:10.1080/03630242.2015.1022814
13. Spaulding AC, Booker CA, Freeman SH, et al. Jails, HIV Testing, and Linkage to Care Services: An Overview of the EnhanceLink Initiative. *AIDS and Behavior*. 2013/10/01 2013;17(2):100-107. doi:10.1007/s10461-012-0339-2
14. Baillargeon J, Giordano TP, Rich JD, et al. Accessing antiretroviral therapy following release from prison. *Jama*. Feb 25 2009;301(8):848-57. doi:10.1001/jama.2009.202
15. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. *PLoS One*. Nov 11 2009;4(11):e7558. doi:10.1371/journal.pone.0007558
16. HIV in Prisons, 2020--Statistical Tables. (2022).
17. North Carolina Department of Health and Human Services. 2019 North Carolina HIV Surveillance Report. Accessed January 23, 2023. https://epi.dph.ncdhhs.gov/cd/stds/figures/hiv18rpt_02042020.pdf
18. Beltran RM, Holloway IW, Hong C, et al. Social Determinants of Disease: HIV and COVID-19 Experiences. *Curr HIV/AIDS Rep*. Feb 2022;19(1):101-112. doi:10.1007/s11904-021-00595-6
19. Buot ML, Docena JP, Ratemo BK, et al. Beyond race and place: distal sociological determinants of HIV disparities. *PLoS One*. 2014;9(4):e91711. doi:10.1371/journal.pone.0091711
20. Zullo AR, Adams JW, Gantenberg JR, Marshall BDL, Howe CJ. Examining neighborhood poverty-based disparities in HIV/STI prevalence: an analysis of Add Health data. *Ann Epidemiol*. Nov 2019;39:8-14.e4. doi:10.1016/j.annepidem.2019.09.010
21. National Center for Medical-Legal Partnership. 2023. <http://medical-legalpartnership.org/>.

22. Vanjani R, Martino S, Reiger SF, et al. Physician-Public Defender Collaboration - A New Medical-Legal Partnership. *N Engl J Med*. Nov 19 2020;383(21):2083-2086. doi:10.1056/NEJMms2002585
23. Mauer M. Addressing Racial Disparities in Incarceration. *The Prison Journal*. 2011/09/01 2011;91(3_suppl):87S-101S. doi:10.1177/0032885511415227
24. NAACP. Criminal Justice Fact Sheet. Accessed March 17, 2023. <https://naacp.org/resources/criminal-justice-fact-sheet>
25. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2014–2018. HIV Surveillance Report. Accessed February 14, 2023. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-1.pdf>
26. Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. *JAMA Intern Med*. May 2014;174(5):721-9. doi:10.1001/jamainternmed.2014.601
27. Camplain R, Warren M, Baldwin JA, Camplain C, Fofanov VY, Trotter RT, 2nd. Epidemiology of Incarceration: Characterizing Jail Incarceration for Public Health Research. *Epidemiology*. Jul 2019;30(4):561-568. doi:10.1097/ede.0000000000001021
28. Centers for Disease Control and Prevention. HIV Surveillance Supplemental Report, 2022. <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/index.html>
29. North Carolina Department of Health and Human Services. HIV Care Outcomes in North Carolina, 2021. Accessed April 11, 2023. <https://epi.dph.ncdhhs.gov/cd/stds/figures/2021-CareOutcomesHIV.pdf>
30. Powers KA, Samoff E, Weaver MA, et al. Longitudinal HIV Care Trajectories in North Carolina. *J Acquir Immune Defic Syndr*. Feb 1 2017;74 Suppl 2(Suppl 2):S88-s95. doi:10.1097/qai.0000000000001234
31. Rebeiro PF, Althoff KN, Lau B, et al. Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected

Adults in North America. *Am J Epidemiol*. Dec 1 2015;182(11):952-60.

doi:10.1093/aje/kwv181

32. Lesko CR, Sampson LA, Miller WC, et al. Measuring the HIV Care Continuum Using Public Health Surveillance Data in the United States. *J Acquir Immune Defic Syndr*. Dec 15 2015;70(5):489-94. doi:10.1097/qai.0000000000000788

33. Miller WC, Lesko CR, Powers KA. The HIV care cascade: simple concept, complex realization. *Sex Transm Dis*. Jan 2014;41(1):41-2.

doi:10.1097/olq.0000000000000081

34. Gray KM, Cohen SM, Hu X, Li J, Mermin J, Hall HI. Jurisdiction level differences in HIV diagnosis, retention in care, and viral suppression in the United States. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2014;65(2):129-132.

35. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed January 24, 2023.

<https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv>

36. Buskin SE, Kent JB, Dombrowski JC, Golden MR. Migration Distorts Surveillance Estimates of Engagement in Care: Results of Public Health Investigations of Persons Who Appear to be Out of HIV Care. *Sexually Transmitted Diseases*. 2014;41(1):35-40.

doi:10.1097/olq.0000000000000072

Supplementary Table 1. Department of public health versus Court record coding of race/ethnicity										
Court Race/ethnicity coding	Department of Public Health Race/ethnicity coding								Row totals	
		Black, non-Hispanic	Black, Hispanic	White, Hispanic	White, non-Hispanic	Asian	American Indian/Alaska native	Other or unknown		
	Black	7226	53	10	47	6	11	0		7353
	White	41	2	58	1742	3	14	0		1860
	Hispanic	7	2	109	11	3	0	1		133
Other or Unknown	70	6	15	52	21	0	4	168		
Column totals	7344	63	192	1852	33	25	5			

medRxiv preprint doi: <https://doi.org/10.1101/2024.04.14.24305790>; this version posted April 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Supplementary Table 2. Baseline characteristics of people with HIV without full follow-up periods (n=2,847)	
	n (col%) or median (1 st -3 rd quartiles)
Sex	
Male	2,228 (78.3)
Female	619 (21.7)
Race	
White	568 (20.0)
Black	2,204 (77.4)
Hispanic	26 (0.9)
Other or Unknown	49 (1.7)
Age (years)	38 (29-50)
Charge days	78 (1-257)
HIV transmission group	
MSM	1,305 (45.8)
Unknown	771 (27.1)
Heterosexual contact	410 (14.4)
IDU	203 (7.1)
MSM & IDU	138 (4.8)
Other	20 (0.7)
Abbreviations: MSM, men who have sex with men; IDU, injection drug use; IQR interquartile range	

Supplementary Table 3. Association¹ between criminal charge period and duration of unresolved charges NC 2017-2020: Results of multivariable log-binomial model (n=6,427)² Analysis including data from all NC counties.

Duration of unresolved charges in days	n (%)	% with viral suppression pre/post charge period	RR of viral suppression in post-charge period compared to pre-charge period
0-99	4,237 (66)	69.8/71.8	1.03 (1.01-1.04)
100-199	984 (15)	72.4/74.3	1.03 (0.90-1.06)
200-299	592 (9)	68.6/72.6	1.06 (1.01-1.10)
300+	604 (10)	64.4/68.1	1.06 (1.01-1.12)

¹ Multivariable log-binomial estimates

² Only individuals who contributed person-time to both pre- and post-charge periods and who had a single period of criminal charges were included in model

medRxiv preprint doi: <https://doi.org/10.1101/2024.04.14.24305790>; this version posted April 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Supplementary Table 4. Baseline characteristics of people with and without HIV who charged in criminal court in NC between 2017-2020. Data limited to 26 counties with jail incarceration data available

Group	Jail Incarcerated and Unincarcerated		Jail Unincarcerated Only		Jail Incarcerated Only	
	Non-HIV (n=155,745)	HIV (n=1,304)	Non-HIV (n=48,846)	HIV (n=494)	Non-HIV (n=105,597)	HIV (n=989)
	n (col%) or median (1 st -3 rd quartiles)					
Sex						
Male	118,267 (75.9)	1,087 (83.4)	37,781 (77.3)	404 (81.8)	79,399 (75.2)	832 (84.1)
Female	37,478 (24.1)	217 (16.6)	11,065 (22.7)	90 (18.2)	26,198 (24.8)	157 (15.9)
Race						
White	72,127 (46.7)	267 (20.5)	20,787 (42.6)	92 (18.6)	51,340 (48.4)	214 (21.6)
Black	72,805 (47.1)	1,005 (77.1)	25,556 (52.3)	391 (79.1)	47,997 (45.0)	748 (75.6)
Hispanic	5,582 (3.6)	12 (0.9)	1,415 (2.9)	3 (0.6)	4,177 (3.9)	10 (1.0)
Other or Unknown	3,034 (2.0)	20 (1.5)	1,088 (2.2)	8 (1.6)	2,158 (2.0)	17 (1.7)
Age (years)	31 (25-40)	37 (28-49)	31 (25-40)	38 (28-49)	31 (24-40)	37 (28-48)
Total number of charge periods						
1	129,870 (84.1)	1,301 (99.8)	35,352 (72.4)	492 (99.6)	94,518 (89.5)	986 (99.7)
2	21,457 (13.9)	3 (0.2)	11,509 (23.6)	2 (0.4)	9,948 (9.4)	3 (0.3)
3 or greater	3,114 (2.0)	0	1,985 (4.1)	0	1,129 (1.1)	0
Charge days	139 (56-270)	121 (37-277)	91 (25-40)	65 (2-182)	165 (73-301)	161 (64-309)
HIV transmission group						
MSM		506 (38.8)		183 (37.0)		387 (39.1)
Unknown		414 (31.7)		151 (30.6)		319 (32.3)
Heterosexual contact		175 (13.4)		74 (15.0)		125 (12.6)
IDU		125 (9.6)		60 (12.1)		90 (9.1)
MSM & IDU		78 (6.0)		24 (4.9)		63 (6.4)
Other		6 (0.5)		2 (0.4)		5 (0.5)

Abbreviations: NC, North Carolina; MSM, men who have sex with men; IDU, injection drug use; IQR interquartile range.

Supplementary Table 5. Viral suppression outcome¹ among people with HIV (PWH) in NC with a single criminal charge between 2017-2020: results of multivariable log-binomial model limited to NC counties with available jail incarceration data².

	26 counties where jail incarceration data available (n=857)	Unincarcerated during charge period (n=246)	Incarcerated during charge period (n=611)
	Adjusted RR (95% CI)³	Adjusted RR (95% CI)³	Adjusted RR (95% CI)³
Criminal Charge Group			
12 months pre charge		Reference	
12 months post charge	0.97 (0.90-1.04)	0.98 (0.89-1.08)	0.98 (0.89-1.07)
Age (years)			
18-29		Reference	
30-39	1.11 (0.96-1.28)	0.96 (0.80-1.14)	1.19 (0.98-1.44)
40-49	1.28 (1.10-1.49)	1.01 (0.81-1.26)	1.41 (1.16-1.71)
50-59	1.49 (1.28-1.74)	1.15 (0.94-1.42)	1.63 (1.33-2.00)
60-69	1.26 (0.93-1.71)	0.91 (0.57-1.44)	1.41 (0.96-2.07)
70 and older	NA	NA	NA
Race/Ethnicity			
White		Reference	
Black	0.83 (0.73-0.93)	0.85 (0.70-1.03)	0.82 (0.71-0.96)
Hispanic	1.59 (1.35-1.89)	1.59 (1.23-2.05)	1.52 (1.15-2.01)
Other	0.93 (0.60-1.44)	0.81 (0.39-1.69)	1.60 (0.84-1.59)
Sex			
Male		Reference	
Female	0.85 (0.72-1.01)	0.92 (0.72-1.18)	0.79 (0.63-0.99)
HIV Transmission Category			
MSM		Reference	
Heterosexual	1.00 (0.85-1.88)	1.66 (0.89-1.49)	0.96 (0.77-1.17)
IDU	0.81 (0.67-0.98)	0.93 (0.72-2.00)	0.78 (0.60-1.00)
MSM and IDU	1.02 (0.82-1.26)	1.12 (0.84-1.50)	0.98 (0.77-1.25)
Other	0.99 (0.77-1.00)	0.93 (0.80-1.09)	1.24 (1.06-1.45)

¹ Multivariable log-binomial model estimates, adjusting for all listed variables. ² Only individuals who contributed person-time to both pre- and post-charge periods and who had a single period of criminal charges were included in

model. ³Adjusted RRs are adjusted for all the variables in the table. Abbreviations: RR, risk ratio; CI, confidence interval; HIV, human immunodeficiency virus; MSM, men who have sex with men; IDU, injection drug use. Definitions: Viral Suppression: <200 copies of HIV RNA per milliliter of blood